← Back to All US Stocks

Streamex Corp. (STEX) Stock Fundamental Analysis & AI Rating 2026

STEX Nasdaq Electromedical & Electrotherapeutic Apparatus DE CIK: 0001530766
Recently Updated • Analysis: Apr 16, 2026 • SEC Data: 2025-12-31
STRONG SELL
85% Conf
Pending
Analysis scheduled

📊 STEX Key Takeaways

Revenue: $-1.6M
Net Margin: 29,068.8%
Free Cash Flow: $-10.6M
Current Ratio: 1.68x
Debt/Equity: 0.00x
EPS: $-9.65
AI Rating: STRONG SELL with 85% confidence
Streamex Corp. (STEX) receives a STRONG SELL rating with 85% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of -$1.6M, net profit margin of 29,068.8%, and return on equity (ROE) of -347.5%, Streamex Corp. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete STEX stock analysis for 2026.

Is Streamex Corp. (STEX) a Good Investment?

Claude

Streamex Corp. exhibits catastrophic operational deterioration with -$462.8M net loss and -$1.6M revenue, indicating severe business distress. The company is burning -$10.4M in operating cash annually with negative gross margins, unsustainable at current trajectory with only ~2 years of cash runway remaining at observed burn rates. Balance sheet equity provides minimal cushion against accelerating operational collapse.

Why Buy Streamex Corp. Stock? STEX Key Strengths

Claude
  • + Positive stockholders equity of $133.2M provides cash reserve cushion
  • + Minimal debt/leverage with 0.00x Debt-to-Equity ratio reduces near-term solvency risk
  • + Current and Quick ratios above 1.6x indicate adequate short-term liquidity position

STEX Stock Risks: Streamex Corp. Investment Risks

Claude
  • ! Catastrophic -$462.8M net loss with -4,080% YoY revenue decline signals severe operational failure or accounting adjustments
  • ! Negative operating cash flow of -$10.4M annually depletes cash reserves; $20.3M cash covers approximately 2 years at current burn rate
  • ! Negative gross margin of -1.1% indicates company loses money on each transaction; unsustainable cost structure
  • ! Operating loss of -$71.1M against minimal revenue suggests fundamental business model breakdown

Key Metrics to Watch

Claude
  • * Operating cash flow trend and runway of cash reserves
  • * Revenue stabilization and gross margin recovery to positive territory
  • * Operating expense reduction and path to profitability
  • * Insider form 4 activity and management confidence signals

Streamex Corp. (STEX) Financial Metrics & Key Ratios

Revenue
$-1.6M
Net Income
$-462.8M
EPS (Diluted)
$-9.65
Free Cash Flow
$-10.6M
Total Assets
$187.5M
Cash Position
$20.3M

💡 AI Analyst Insight

The 667.3% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.

STEX Profit Margin, ROE & Profitability Analysis

Gross Margin -1.1%
Operating Margin 4,465.7%
Net Margin 29,068.8%
ROE -347.5%
ROA -246.8%
FCF Margin 667.3%

STEX vs Healthcare Sector: How Streamex Corp. Compares

How Streamex Corp. compares to Healthcare sector averages

Net Margin
STEX 29,068.8%
vs
Sector Avg 12.0%
STEX Sector
ROE
STEX -347.5%
vs
Sector Avg 15.0%
STEX Sector
Current Ratio
STEX 1.7x
vs
Sector Avg 2.0x
STEX Sector
Debt/Equity
STEX 0.0x
vs
Sector Avg 0.6x
STEX Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Streamex Corp. Stock Overvalued? STEX Valuation Analysis 2026

Based on fundamental analysis, Streamex Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-347.5%
Sector avg: 15%
Net Profit Margin
29,068.8%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.00x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Streamex Corp. Balance Sheet: STEX Debt, Cash & Liquidity

Current Ratio
1.68x
Quick Ratio
1.63x
Debt/Equity
0.00x
Debt/Assets
28.9%
Interest Coverage
-44.43x
Long-term Debt
N/A

STEX Revenue & Earnings Growth: 5-Year Financial Trend

STEX 5-year financial data: Year 2024: Revenue $40.0K, Net Income -$29.0M, EPS $-3.95. Year 2025: Revenue $40.0K, Net Income -$10.3M, EPS $-0.75.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Streamex Corp.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.75 indicates the company is currently unprofitable.

STEX Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
667.3%
Free cash flow / Revenue

STEX Quarterly Earnings & Performance

Quarterly financial performance data for Streamex Corp. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $27.0K -$1.9M $-0.12
Q2 2025 $13.0K -$3.9M $-0.30
Q1 2025 $14.0K -$2.8M $-0.14
Q3 2024 $1.0K -$1.9M $-0.12

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Streamex Corp. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$10.4M
Cash generated from operations
Capital Expenditures
$186.0K
Investment in assets
Dividends
None
No dividend program

STEX SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Streamex Corp. (CIK: 0001530766)

📋 Recent SEC Filings

Date Form Document Action
Apr 10, 2026 8-K form8-k.htm View →
Mar 31, 2026 10-K form10-k.htm View →
Mar 27, 2026 8-K form8-k.htm View →
Mar 26, 2026 4 xslF345X06/ownership.xml View →
Mar 20, 2026 8-K form8-k.htm View →

Frequently Asked Questions about STEX

What is the AI rating for STEX?

Streamex Corp. (STEX) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.

What are STEX's key strengths?

Claude: Positive stockholders equity of $133.2M provides cash reserve cushion. Minimal debt/leverage with 0.00x Debt-to-Equity ratio reduces near-term solvency risk.

What are the risks of investing in STEX?

Claude: Catastrophic -$462.8M net loss with -4,080% YoY revenue decline signals severe operational failure or accounting adjustments. Negative operating cash flow of -$10.4M annually depletes cash reserves; $20.3M cash covers approximately 2 years at current burn rate.

What is STEX's revenue and growth?

Streamex Corp. reported revenue of $-1.6M.

Does STEX pay dividends?

Streamex Corp. does not currently pay dividends.

Where can I find STEX SEC filings?

Official SEC filings for Streamex Corp. (CIK: 0001530766) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is STEX's EPS?

Streamex Corp. has a diluted EPS of $-9.65.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is STEX a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Streamex Corp. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is STEX stock overvalued or undervalued?

Valuation metrics for STEX: ROE of -347.5% (sector avg: 15%), net margin of 29,068.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy STEX stock in 2026?

Our dual AI analysis gives Streamex Corp. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.

What is STEX's free cash flow?

Streamex Corp.'s operating cash flow is $-10.4M, with capital expenditures of $186.0K. FCF margin is 667.3%.

How does STEX compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin 29,068.8% (avg: 12%), ROE -347.5% (avg: 15%), current ratio 1.68 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 16, 2026 | Data as of: 2025-12-31 | Powered by Claude AI